Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

at a significantly lower cost — around $250 to $350 per month for tirzepatide, compared to Zepbound's list price of $1,059. With the official shortage over, the FDA has signaled it will crack ...

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...

Weight loss efficacy: While both medications are highly effective for weight loss, studies suggest tirzepatide may lead to greater reductions in body weight due to its dual-action mechanism. Cost ...

Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...

leading to inequality of access and patient outcomes services that already exist would need to be decommissioned to provide the resources required to deliver tirzepatide. Budget impact: The ...